QY Research has published a new research study on the global biosimilar monoclonal antibodies market. Added to the pharma and healthcare archive of research studies, the report bears the title “Global Biosimilar Monoclonal Antibodies Market Report, History and Forecast 2014-2025.” It offers comprehensive and accurate insights into the market competition, segmentation, regional advancement, and other critical aspects. The global biosimilar monoclonal antibodies market is anticipated to expand at an exponential CAGR of 27.7% during the forecast period 2019-2025. The global market valuation is projected to reach US$15.2 Bn by 2025, jumping from US$2.7 Bn obtained in 2018.
Global Biosimilar Monoclonal Antibodies Market: Market Dynamics
Market analysts say there could be opportunities opening up in the global biosimilar monoclonal antibodies market as monopoly drugs or generic biologics reach their patent expiry dates. There are also various other types of drugs that have already been expired. Some of the traditional patented drugs sold in the market may not be affordable for patients. Thus, the availability of cost-effective alternatives that reduce the cost burden of patients could be another factor pushing the growth of the global market.
The demand for biosimilar drugs is expected to increase on the back of the need for low-cost medications, especially in developing countries. The global biosimilar monoclonal antibodies market is predicted to gain support from the growing incidence of different cancer types, oncological disorders, and other chronic diseases. Heavy investment of pharmaceutical companies in the research and development of biosimilar drugs is foreseen to augment the demand in the global market.
However, tight government regulations and expensive manufacturing cost are foretold to pose challenges to manufacturers of biosimilar monoclonal antibodies.
Global Biosimilar Monoclonal Antibodies Market: Segmental Analysis
According to the report, the global biosimilar monoclonal antibodies market could be segmented as per type of product and application. The report analyzes five product type segments, viz. adalimumab, trastuzumab, rituximab, infliximab, and others. Among these, infliximab attained a larger share of the global market in terms of sales.
On the basis of application, the global market is segmented into autoimmune disease, oncology, and others. Among these, autoimmune disease secured a remarkable share of the global market in terms of consumption and sales.
Global Biosimilar Monoclonal Antibodies Market: Regional Study
Regionally, the global biosimilar monoclonal antibodies market is segmented into South America, the MEA, North America, Asia Pacific, and Europe. All of the regions studied in the report are deeply looked into with key focus on their consumption, production, revenue, sales, and other factors that define their growth in the global market.
Global Biosimilar Monoclonal Antibodies Market: Competition
The authors of the report have profiled key manufacturers operating in the global biosimilar monoclonal antibodies market, viz. Torrent Pharmaceuticals, Hisun Pharmaceuticals, Cadila Healthcare, Celgen Biopharma, Dr. Reddy’s, Novartis (Sandoz), 3SBIO, Pfizer (Hospira), and Celltrion. New entrants are expected to find it difficult to maintain a strong position in the global market. Each player analyzed in the report is studied based on recent developments, market share, areas served, and other vital factors.